ClinicalTrials.gov
public full text
Public Domain
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ovarian Screening Study#900570
- Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test#1029971
- Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.#812440
- Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer#862225
- A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics#836787
Record · ID 872302
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive